Table 1.

In vitro antitumor activity.

Compound	IC50 (µM) ± S.D.
	2008	MCF-7	A431	HCT-15	H157	Average
[Pt(CBDCA)(cis-1,4-DACH)]	25.47 ± 4.11	20.58 ± 3.15	13.56 ± 2.18	30.58 ± 5.25	19.21 ± 4.15	21.9
2	3.15 ± 0.85	3.05 ± 0.89	2.25 ± 0.52	2.31 ± 0.56	3.44 ± 0.97	2.8
3	0.34 ± 0.09	1.12 ± 0.57	0.10 ± 0.04	0.61 ± 0.15	0.99 ± 0.31	0.6
CDDP	2.22 ± 1.02	10.58 ± 0.82	2.10 ± 0.87	15.28 ± 2.63	2.12 ± 0.89	6.5
OXP	1.65 ± 0.46	4.52 ± 0.95	3.71 ± 0.76	1.15 ± 0.43	5.99 ± 1.85	3.4
Kiteplatin	1.89 ± 1.04	3.10 ± 1.42	3.95 ± 1.11	2.66 ± 0.95	2.08 ± 0.66	2.7

CDDP: cisplatin, OXP: oxaliplatin. S.D. = standard deviation. Cells (3–5 × 10⁴ mL⁻¹) were treated for 72 h with different concentrations of tested compounds. Cytotoxicity was assessed by the MTT test. IC₅₀ values were calculated by a four parameter logistic model (p < 0.05).